Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares shot up 10.2% on Tuesday . The stock traded as high as $16.56 and last traded at $16.42. 118,927 shares changed hands during trading, a decline of 47% from the average session volume of 224,239 shares. The stock had previously closed at $14.90.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on the company. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Guggenheim started coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $45.00 target price on the stock. Finally, TD Cowen assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating for the company.
Get Our Latest Stock Analysis on SION
Sionna Therapeutics Stock Performance
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
